Markets & Regulations

© GettyImages/Andrew Brookes

Needle-free future: Tackling vaccine delivery challenges

By Jane Byrne

Biotech company, Vaxxas, has secured a partnership agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its needle-free vaccine-patch delivery technology for mRNA vaccines.

© GettyImages/ArtemisDiana

Lumen Bio: ‘We face 2023 with tremendous optimism’

By Jane Byrne

Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.

© GettyImages/AlexanderFord

Opus acquires two compounds for inherited retinal diseases

By Jane Byrne

Last week saw Opus Genetics announce it had acquired the rights to two preclinical-stage adeno-associated virus (AAV)-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio.

Follow us

Webinars